Wolfe Research has downgraded Akero Therapeutics Inc (AKRO) to a Peer Perform rating from Outperform as of October 9, 2025. The current share price stands at $54.28.
This move underscores increased caution regarding the company's outlook, potentially reflecting concerns about competitive pressures, market conditions, or execution risks that could impact its performance. Akero Therapeutics, a clinical-stage biotechnology company headquartered in South San Francisco, focuses on developing treatments for serious metabolic diseases. Its lead product candidate, Efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 studies targeting patients with metabolic dysfunction-associated steatotic liver disease (MASH).
With a market capitalization of $4.5 billion and a trailing twelve-month EPS of -3.75, Akero's financial performance has shown volatility in recent quarters. The company has upcoming earnings reports scheduled for May 11, 2026, and August 6, 2026, with EPS estimates of -1.05 and -1.09, respectively. Recent earnings have seen mixed results, with Q3 2025 reporting an EPS of -0.98, slightly below the estimate of -0.94.
Analyst ratings play a crucial role in shaping investor perspectives. As of November 1, 2025, the consensus rating for Akero is classified as Buy, with 2 Strong Buy, 7 Buy, and 7 Hold ratings among 16 analysts. Notably, several analysts have recently adjusted their ratings, reflecting a shift in sentiment toward the company.
Such decisions reflect the dynamic nature of the biotechnology sector, where new information can significantly alter the outlook for companies like Akero Therapeutics.